Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.56 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9547833 | 0.93 | AKR1C2 (0.51) | ESR1ESR2PDCD1CD274LMNA | |
| SCHEMBL1338710 | 0.87 | AKR1C2 (0.42) | ESR1ESR2PDCD1CD274TDP1 | |
| SCHEMBL17602077 | 0.86 | ESR1 (0.43) | ESR1ESR2PDCD1CD274LMNA | |
| SCHEMBL17789898 | 0.84 | ESR1 (0.50) | ESR1ESR2PDCD1CD274LMNA | |
| Methoxymethane SCHEMBL9478009 | 0.83 | ESR1 (0.54) | ESR1ESR2PDCD1CD274LMNA | |
| SCHEMBL9479827 | 0.82 | ESR1 (0.59) | ESR1ESR2PDCD1CD274LMNA | |
| SCHEMBL8750439 | 0.79 | IDO1 (0.43) | LMNACYP2D6CYP2C9PTGS1AKR1C2 | |
| SCHEMBL28950031 | 0.78 | ESR1 (0.54) | ESR1ESR2PDCD1CD274LMNA | |
| SCHEMBL18905322 | 0.77 | AKR1C2 (0.38) | AKR1C2AKR1C1 | |
| SCHEMBL4518522 | 0.77 | AKR1C2 (0.38) | AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119080589-A | Preparation method of p-methoxyethylphenol | 常州瑞明药业有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-119019231-A | Preparation method of p-methoxyethylphenol | 常州瑞明药业有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-117209653-B | Three-chain-segment polymer dispersing agent, preparation method thereof and lithium manganese iron phosphate positive electrode slurry | 江苏一特新材料有限责任公司 | 2024-01-02 | — | — | CN | claimed |
| CN-117209653-A | Three-chain-segment polymer dispersing agent, preparation method thereof and lithium manganese iron phosphate positive electrode slurry | 江苏一特新材料有限责任公司 | 2023-12-12 | — | — | CN | claimed |
| CN-114702372-B | Method for preparing 4- (2-methoxyl) ethylphenol | 台州市前进化工有限公司 | 2022-12-16 | — | — | CN | claimed |
| CN-115304500-A | Method for synthesizing metoprolol impurity | 北京康派森医药科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-114702372-A | Method for preparing high-purity 4- (2-methoxy) ethylphenol | 台州市前进化工有限公司 | 2022-07-05 | — | — | CN | claimed |
| CN-113150287-A | Preparation method of cross-linkable fluorine-containing polyphosphazene | 北京化工大学 | 2021-07-23 | — | — | CN | claimed |
| CN-111517967-A | Method for synthesizing metoprolol succinate isomer impurity | 山东齐都药业有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-111196783-A | 2,4, 6-substituted pyrimidine derivatives containing acyl urea structure, and preparation method and application thereof | 郑州大学 | 2020-05-26 | — | — | CN | claimed |
| WO-2010024841-A1 | NEW PROPANOATES AND PROCESSES FOR PREPARING THE SAME | DUPONT ELECTRONIC POLYMERS L.P. (US) | 2010-03-04 | — | — | WO | claimed |
| US-20100047714-A1 | New propanoates and processes for preparing the same | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2010-02-25 | — | — | US | claimed |
| US-20080214874-A1 | Derivatized polyhydroxystyrenes with a novolak type structure and processes for preparing the same | SHEEHAN MICHAEL T | 2008-09-04 | — | — | US | claimed |
| US-7371800-B2 | Derivatized novolak polyhydroxystyrene from hydroxyphenylmethylcarbinol | DUPONT ELECTRONIC POLYMERS L.P. (US) | 2008-05-13 | — | — | US | claimed |
| EP-1756191-A1 | DERIVATIZED POLYHYDROXYSTYRENES WITH A NOVOLAK TYPE STRUCTURE AND PROCESSES FOR PREPARING THE SAME | Dupont Electronic Polymers L.P. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2006052380-A1 | DERIVATIZED POLYHYDROXYSTRYRENE (DPHS)WITH A NOVOLAK TYPE STRUCTURE AND BLOCKED DPHS (BDPHS) AND PROCESSES FOR PREPARING THE SAME | DUPONT ELECTRONIC POLYMERS L.P. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060099531-A1 | Derivatized polyhydroxystyrenes (DPHS) with a novolak type structure and blocked DPHS (BDPHS) and processes for preparing the same | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2006-05-11 | — | — | US | claimed |
| WO-2005113634-A1 | DERIVATIZED POLYHYDROXYSTYRENES WITH A NOVOLAK TYPE STRUCTURE AND PROCESSES FOR PREPARING THE SAME | DUPONT ELECTRONIC POLYMERS L.P. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050250042-A1 | Derivatized polyhydroxystyrenes with a novolak type structure and processes for preparing the same | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2005-11-10 | — | — | US | claimed |
| EP-0357310-B1 | Process for producing substituted phenoxyethylamines and intermediates | UBE INDUSTRIES (JP) | 1994-03-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047714-A1 | New propanoates and processes for preparing the same | HPD, HMBS, LDHB | ESR1 1760/4885ESR2 2692/4885PDCD1 3014/4885 |
| US-20080214874-A1 | Derivatized polyhydroxystyrenes with a novolak type structure and processes for preparing the same | VRK1, VRK2, CHKB | ESR1 1023/4885ESR2 997/4885PDCD1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.